The U.S. Food and Drug Administration (FDA) has updated the label information for the commonly used anti-clotting medication Plavix® (clopidogrel) to stress to physicians that patients carrying certain genetic variations may not receive the full benefit from the drug.
Plavix reduces the chance a harmful clot will develop by preventing blood cells called platelets from sticking [...]

Tags: black box, boxed warning, clopidogrel, CYP2C19, Effient, FDA, metabolizer, Plavix, prasugrel

Warfarin (Coumadin®) is a blood thinner given to people at high risk for the formation of blood clots due to conditions such as deep vein thrombosis, heart valve disease or replacement, and irregular heart beat. The drug is also given to prevent recurrence of pulmonary embolism, heart attack and stroke.
If too little warfarin is prescribed, [...]

Tags: CDER, CMS, Coumadin, FDA, warfarin